Zanubrutinib versus bendamustine and rituximab in untreated patients with CLL/SLL Zanubrutinib versus bendamustine and rituximab in untreated patients with CLL/SLL February 2025 Clinical trials Read more
2024 May Clinical practice CPX-351 in high-risk AML patients: Insights from Real-World data Read more
2022 November Clinical trials No survival benefit from adding gilteritinib to azacitidine in newly-diagnosed FLT3-mutated pa... Read more
2022 November Clinical trials Ivosidenib plus azacitidine for patients with IDH1-mutated acute myeloid leukaemia Read more
2022 May ASH 2021 Axicabtagene ciloleucel: potential new second-line standard of care for patients with relapsed... Read more
2022 May ASH 2021 Daratumumab plus VCd as a new standard of care for patients with newly diagnosed light-chain a... Read more
2021 April Editor's pick RELEVANT LITERATURE FOR YOUR DAILY PRACTICE SELECTED BY: ACHIEL VAN HOOF Read more